OGN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

8.805

Open

8.560

VWAP

8.55

Vol

6.96M

Mkt Cap

2.26B

Low

8.130

Amount

59.43M

EV/EBITDA(TTM)

5.99

Total Shares

260.32M

EV

10.29B

EV/OCF(TTM)

14.70

P/S(TTM)

0.36

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Show More

Events Timeline

(ET)

2026-04-10

16:10:00

S&P 500 Closes Slightly Lower on Friday Amid Oil Volatility

2026-04-10

12:00:00

Dow Jones Falls, Nasdaq Rises as Markets Mixed

2026-04-10

09:30:00

Evercore ISI: Sun Pharmaceutical Plans $12B Bid for Organon

2026-04-10

09:30:00

Sun Pharmaceutical Clarifies Organon Acquisition Speculation

2026-04-10

09:00:00

Stock Futures Flat as Market Awaits Confirmation

2026-04-10

08:00:00

Sun Pharmaceutical to Acquire Organon for $12 Billion

2026-03-27 (ET)

2026-03-27

08:10:00

Organon to Present Vtama Study Results at 2026 American Academy of Dermatology Annual Meeting

News

seekingalpha

04-11seekingalpha

Key Deals Reported Across Sectors This Week

Yahoo Finance

04-11Yahoo Finance

Market Remains Cautious as Oil Approaches $100 Amid Inflation Concerns

Yahoo Finance

04-10Yahoo Finance

Health Care Stocks Decline 1.1% on NYSE

CNBC

Chip Stocks Surge as Investors Favor Semiconductors Over Software

seekingalpha

04-10seekingalpha

Sun Pharma Submits $12B Bid for Organon, Shares Surge

stocktwits

04-10stocktwits

Sun Pharma Faces Competition for Organon Acquisition

5 Analyst Rating

Wall Street analysts forecast OGN stock price to rise

0 Buy

1 Hold

4 Sell

Strong Sell

Current: 0.000

Low

5.00

Averages

8.50

High

12.00

Current: 0.000

Low

5.00

Averages

8.50

High

12.00

BNP Paribas

Outperform

maintain

$12

AI Analysis

2026-04-10

New

Reason

BNP Paribas

Price Target

$12

AI Analysis

2026-04-10

New

maintain

Outperform

Reason

BNP Paribas keeps an Outperform rating on Organon (OGN) with a $12 price target after the Economic Times reported Sun Pharmaceutical is set to make a $12B offer for the company. Assuming an enterprise value of $12B, the potential offer could represent a fair value of $15 per share, or 115% upside from yesterday's close, the analyst tells investors in a research note. BNP believes a potential deal with Sun Pharma could be a positive. It notes the shares have been under pressure amid an investigation into improper sales practices for Nexplanon and funding cuts to Planned Parenthood. Organon shares in morning trading are up 26%, or $1.83, to $8.74.

Barclays

Underweight

maintain

$8

2026-02-24

Reason

Barclays

Price Target

$8

2026-02-24

maintain

Underweight

Reason

Barclays raised the firm's price target on Organon to $8 from $7.50 and keeps an Underweight rating on the shares. The firm updated the company's model post the Q4 report.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Organon & Co (OGN.N) is 5.09, compared to its 5-year average forward P/E of 4.85. For a more detailed relative valuation and DCF analysis to assess Organon & Co's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

4.85

Current PE

5.09

Overvalued PE

6.34

Undervalued PE

3.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

6.61

Current EV/EBITDA

6.96

Overvalued EV/EBITDA

7.72

Undervalued EV/EBITDA

5.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

0.86

Current PS

0.37

Overvalued PS

1.23

Undervalued PS

0.49

Financials

AI Analysis

Annual

Quarterly

Whales Holding OGN

Private Management Group Inc

Cobas Asset Management, SGIIC, SA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Organon & Co (OGN) stock price today?

The current price of OGN is 8.7 USD — it has increased 1.87

What is Organon & Co (OGN)'s business?

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

What is the price predicton of OGN Stock?

Wall Street analysts forecast OGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGN is8.50 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Organon & Co (OGN)'s revenue for the last quarter?

Organon & Co revenue for the last quarter amounts to 1.51B USD, decreased -5.34

What is Organon & Co (OGN)'s earnings per share (EPS) for the last quarter?

Organon & Co. EPS for the last quarter amounts to -0.79 USD, decreased -288.10

How many employees does Organon & Co (OGN). have?

Organon & Co (OGN) has 10000 emplpoyees as of April 15 2026.

What is Organon & Co (OGN) market cap?

Today OGN has the market capitalization of 2.26B USD.